Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

Quality of Life and Adverse Effects in Epilepsy Patients According to Treatment Group (EPIKA)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00302991

Enrollment

180

Registered

2006-03-15

Start date

2006-03-31

Completion date

2007-10-31

Last updated

2008-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

Observational, cross-sectional, health-related quality of life, adverse effects, Baker´s AEP scale validation, epilepsy

Brief summary

Observational, multicentre, epidemiological study to determine the HRQOL of patients with epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients receiving only a new anti-epilepsy drug (AED), patients receiving a classic AED; patients receiving combination therapy.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Epileptic adult patients treated at a stable dose with one or more AEDs for ≥ 3 months

Exclusion criteria

* Symptomatic epilepsy due to malignant brain tumour or progressive brain disease. * Confirmed diagnosis of a concomitant chronic disease

Countries

Spain

Outcome results